Promising results from clinical study using plasmid DNA gene therapy: Hope for critical limb ischemia patients - (Science Daily via NewsPoints Desk)

  • Study data published in the journal Gene Therapy describe the efficacy of a human hepatocyte growth factor (HGF)-based gene therapy named VM202 in the treatment of critical limb ischaemia, Science Daily reported.
  • "These positive results are exciting, and VM202 shows great promise for treating patients with this debilitating disease who often have limited therapeutic options," said study author Emerson C. Perin.
  • In the study, the researchers observed that treatment with high-dose VM202 completely healed ulcers in 62 percent of patients, compared to 11 percent of patients treated with placebo.
  • The researchers also found that 71 percent of patients in the high-dose VM202 group displayed improved tissue oxygenation, versus 33 percent of placebo-treated patients.
  • "We are looking forward to conducting a phase III trial to better understand the potential of this novel approach, especially in treating non-healing ulcers, which is a serious symptom that often leads to amputation because of the lack of medical therapies available," Perin stated.
  • The study was partially funded by ViroMed, which is developing VM202 for the treatment of ischaemic foot ulcers in patients with diabetes.

To read more NewsPoints articles, click here.